These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3457102)

  • 1. Neurotoxicity associated with systemic high-dose cytosine arabinoside.
    Nand S; Messmore HL; Patel R; Fisher SG; Fisher RI
    J Clin Oncol; 1986 Apr; 4(4):571-5. PubMed ID: 3457102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytosine arabinoside for acute nonlymphocytic leukemia.
    Cantin G; Brennan JK
    Am J Hematol; 1984 Jan; 16(1):59-66. PubMed ID: 6695910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM; Cortes-Franco J; Estey E
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cytosine arabinoside therapy for refractory leukemia.
    Herzig RH; Wolff SN; Lazarus HM; Phillips GL; Karanes C; Herzig GP
    Blood; 1983 Aug; 62(2):361-9. PubMed ID: 6223674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytosine-arabinoside in the treatment of acute leukemias].
    Böhnel J; Gingold N; Hermansky F; Pawlowski M; Stacher A
    Wien Med Wochenschr; 1972 Apr; 122(15):203-7. PubMed ID: 4527321
    [No Abstract]   [Full Text] [Related]  

  • 8. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
    Powell BL; Capizzi RL; Lyerly ES; Cooper MR
    J Clin Oncol; 1986 Jan; 4(1):95-7. PubMed ID: 3001234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of refractory leukemia with high-dose cytosine arabinoside.
    Klener P; Háber J
    Neoplasma; 1985; 32(1):113-7. PubMed ID: 3856754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
    Saito T; Asai O; Dobashi N; Yano S; Osawa H; Takei Y; Takahara S; Ogasawara Y; Yamaguchi Y; Minami J; Usui N
    J Infect Chemother; 2006 Jun; 12(3):148-51. PubMed ID: 16826348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system toxicity of high-dose cytosine arabinoside.
    Grossman L; Baker MA; Sutton DM; Deck JH
    Med Pediatr Oncol; 1983; 11(4):246-50. PubMed ID: 6888324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
    Lin SF; Liu HW; Chen TP
    Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia.
    Cold S
    Scand J Haematol; 1986 Feb; 36(2):165-7. PubMed ID: 3458292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
    Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
    Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
    Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
    Rubin EH; Andersen JW; Berg DT; Schiffer CA; Mayer RJ; Stone RM
    J Clin Oncol; 1992 Jun; 10(6):948-53. PubMed ID: 1588374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.